Clinical trials: CHC
Esophageal Neoplasm
Definitive Radiotherapy for Cervical and Upper Thoracic Esophageal Cancer (ChC&UES): A Multi-center Real World Study
Cervical and upper thoracic esophageal cancer (ESCA) presents treatment challenges due to limited clinical evidence. This multi-center study (ChC\&UES) explores radical radio(chemo)therapy efficacy and safety
- Trial name
- NCT06481449
- Where
- China
- Volunteers
- 2,600 people
- Sponsor
- Hebei Medical University Fourth Hospital
Hepatitis C, Chronic
HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)
This study evaluated the safety and efficacy of peginterferon alfa-2a monotherapy in participants with Chronic Hepatitis C (CHC) who have End-Stage Renal Disease (ESRD) and were undergoing hemodialysis.
- Trial name
- NCT02806505
- Testing
- Peginterferon alfa-2a
- Where
- 22 sites in Austria, Brazil and 6 more
- Volunteers
- 81 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic, Insulin Resistance
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1.
- Trial name
- NCT00493805
- Testing
- Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Viral, Chronic Kidney Disease stage3
A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir
The regimen using grazoprevir plus elbasvir treatment is promising in Japan, because it may safely be used for the elderly patients with renal dysfunction.
- Trial name
- NCT03144635
- Testing
- Grazoprevir plus Elbasvir
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Kyushu University
Hepatitis C, Chronic
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
This 4 arm study is designed for patients with CHC who have not responded to peginterferon alfa-2b (12KD)/ribavirin combination therapy.
- Trial name
- NCT00087646
- Testing
- Ribavirin, peginterferon alfa-2a [Pegasys]
- Where
- 104 sites in United States, Belgium and 12 more
- Volunteers
- 948 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C
This study is a multi-center, randomized, open-label and positive controlled Phase II Clinical trial to assess the efficacy and safety of Ypeginterferon alfa-2b (with Ribavirin), once a week, in 3 dose-groups respectively, for…
- Trial name
- PEGIFN (NCT01140997)
- Testing
- Ypeginterferon alfa-2b, Peginterferon alfa-2a
- Where
- 38 sites in China
- Volunteers
- 211 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Hepatitis C
Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C
The study is a first in man, dose escalation study that will measure the safety and efficacy of TT-034 in the treatment of patients with chronic hepatitis C. The study is divided into 5 dose levels.
- Trial name
- NCT01899092
- Testing
- TT-034
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Tacere Therapeutics, Inc.
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
This randomized, parallel arm study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in combination with 2 different doses of ribavirin in patients with chronic hepatitis C, genotype 2 or 3.
- Trial name
- NCT01258101
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin
- Where
- 18 sites in Austria
- Volunteers
- 395 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis
This prospective observational study will evaluate the efficacy and safety of peginterferon alfa-2a in combination with ribavirin in participants with chronic hepatitis C, including participants with compensated liver cirrhosis…
- Trial name
- STANDART (NCT01609049)
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 57 sites in Russia, South Korea
- Volunteers
- 1,496 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel
Primary objective: 1. To estimate the effectiveness of treatment with FDC of Zepatier with or without ribavirin in Israeli patients with CHC and advanced fibrosis in real life setting. Secondary objective: 1.
- Trial name
- NCT03144440
- Volunteers
- 200 people
- Sponsor
- Carmel Medical Center
Chronic Hepatitis C
The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs
Hepatitis C virus (HCV) infection is easy to chronic and can progress to cirrhosis and liver cancer. Direct-acting antiviral treatment can significantly improve the prognosis of the disease and the efficacy is seemingly not…
- Trial name
- NCT03188276
- Testing
- Ledipasvir-Sofosbuvir, Daclatasvir-Sofosbuvir
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C, Chronic
8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis
Grazoprevir plus elbasvir 12 to 16 weeks is now approved for chronic hepatitis C (CHC) genotype 1, 4, or 6 infection regardless liver disease severity.
- Trial name
- NCT03186365
- Testing
- Zepatier Oral Product
- Where
- Taiwan
- Volunteers
- 82 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C Virus (HCV)
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
This study will assess the safety and effectiveness of Maviret (Glecaprevir plus Pibrentasvir (GLE/PIB)) in adolescent participants diagnosed with chronic hepatitis C (CHC) in a real world setting across clinical practice in…
- Trial name
- NCT04214028
- Where
- 54 sites in Japan
- Volunteers
- 50 people
- Sponsor
- AbbVie
Hepatitis C, Chronic, Healthy Volunteer
A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C
This 2-part, randomized, double-blind, placebo-controlled study will assess the safety, pharmacokinetics and pharmacodynamics of RO5428029 in healthy volunteers and patients with hepatitis C infection.
- Trial name
- NCT01371162
- Testing
- RO5428029
- Where
- 6 sites in France, Netherlands and 1 more
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C (Disorder)
Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs
Recently,surprisingly and unexpectedly increased aggressiveness and high rates of HCC recurrence (28%(16/58) and 29%(17/59), respectively) have been reported in patients who cleared HCV with DAAs after achieving a complete…
- Trial name
- NCT03063723
- Testing
- Ledipasvir-Sofosbuvir, Daclatasvir-Sofosbuvir
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Lipoprotein Disorder
A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center
A multi-center, prospective, observational Study to describe the siTuation of blood lipid mAnagement among the population with hypeRtension and/or type 2 diabeTes in Community Health Center
- Trial name
- NCT05081440
- Volunteers
- 5,000 people
- Sponsor
- Huashan Hospital
Chronic Hepatitis C
Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin
Genotype 1 CHC participants from Study SPC3649-207 with null response to prior pegylated-interferon alpha plus ribavirin will be enrolled into this 36-month extension study, designed to evaluate the long-term safety and efficacy…
- Trial name
- NCT02508090
- Where
- Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.
This study will evaluate the efficacy and safety of 4 regimens of PEGASYS plus Copegus, in patients with chronic hepatitis C (CHC) genotype 1 who have failed to respond to previous treatment with standard doses of PEGASYS plus…
- Trial name
- NCT00412334
- Testing
- Copegus, peginterferon alfa-2a [Pegasys]
- Where
- 22 sites in France
- Volunteers
- 104 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment
This study will evaluate the pharmacokinetics (area under the curve [AUC], maximum concentration [Cmax], and other parameters) and tolerability of peginterferon alfa-2a and ribavirin combination therapy following single and…
- Trial name
- NCT02864199
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 17 sites in United States, Brazil and 3 more
- Volunteers
- 63 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
The purpose of this study is to evaluate the efficacy and safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.
- Trial name
- NCT03020082
- Testing
- Danoprevir, Ritonavir, peginterferon alfa-2a
- Volunteers
- 141 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.